Venmax Drugs and Pharmaceuticals Ltd

📊 Venmax Drugs FY26: Revenue jumps to ₹802.49 Lakhs, PAT turns positive

- Turnover: ₹802.49 Lakhs (prev yr ₹80.73 Lakhs)

- PAT: ₹24.82 Lakhs (prev yr loss of (1.05) Lakhs)

- Cash & equivalents: ₹122.36 Lakhs (Mar 31, 2026)

- ₹24.82 Lakhs transferred to General Reserve

- Paid-up capital: ₹5,23,89,300/- to ₹11,58,29,300/-

- 63,44,000 Convertible Warrants converted into Equity Shares

- 36,81,000 Convertible Warrants outstanding as on Mar 31, 2026

- No dividend recommended on Equity Shares

- Scheme of Amalgamation with Hatri Pharma pending NCLT approval

- Post Mar 31: 29,00,999 warrants converted, 7,80,001 forfeited